Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Myeloid, Acute 15Myelodysplastic Syndromes 10Recurrence 7Ovarian Neoplasms 7Multiple Myeloma 7Pancreatic Neoplasms 6Lymphoma 6Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Colorectal Neoplasms 5Burkitt Lymphoma 5Stomach Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hodgkin Disease 4Hematologic Neoplasms 4Sarcoma 3Osteosarcoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia, Biphenotypic, Acute 3Leukemia, B-Cell 3Leukemia 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Triple Negative Breast Neoplasms 2Thymoma 2

Interventions

lenvatinib 1fludarabine 1aldesleukin 1Nivolumab 1Masks 1Ipilimumab 1Gemcitabine 1Everolimus 1Cyclophosphamide 1CTLA-4 Antigen 1Behavioral Sciences 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × fludarabine × 30 days × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡